Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 148 entries
Sorted by: Best Match Show Resources per page
Molecular serum markers of liver fibrosis.

Biomarker insights

Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F.
PMID: 22872786
Biomark Insights. 2012;7:105-17. doi: 10.4137/BMI.S10009. Epub 2012 Jul 23.

Fibrosis is a hallmark histologic event of chronic liver diseases and is characterized by the excessive accumulation and reorganization of the extracellular matrix (ECM). The gold standard for assessment of fibrosis is liver biopsy. As this procedure has various...

Cite
Liu T, Wang X, Karsdal MA, et al. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105-17doi: 10.4137/BMI.S10009.
Liu, T., Wang, X., Karsdal, M. A., Leeming, D. J., & Genovese, F. (2012). Molecular serum markers of liver fibrosis. Biomarker insights, 7105-17. https://doi.org/10.4137/BMI.S10009
Liu, Tianhui, et al. "Molecular serum markers of liver fibrosis." Biomarker insights vol. 7 (2012): 105-17. doi: https://doi.org/10.4137/BMI.S10009
Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105-17. doi: 10.4137/BMI.S10009. Epub 2012 Jul 23. PMID: 22872786; PMCID: PMC3412619.
Copy Download .nbib Format: NLM
Computable Information Governance Contracts.

Studies in health technology and informatics

Cunningham J, Leeming G, Ainsworth J.
PMID: 28423838
Stud Health Technol Inform. 2017;235:476-480.

The risks of relinquishing control of electronic healthcare data for re-use in research are mitigated by the use of data sharing agreements and information governance procedures. These exist as legal, or quasi-legal, textual documents exchanged between data owners. Their...

Cite
Cunningham J, Leeming G, Ainsworth J. Computable Information Governance Contracts. Stud Health Technol Inform. 2017;235:476-480
Cunningham, J., Leeming, G., & Ainsworth, J. (2017). Computable Information Governance Contracts. Studies in health technology and informatics, 235476-480.
Cunningham, James, et al. "Computable Information Governance Contracts." Studies in health technology and informatics vol. 235 (2017): 476-480.
Cunningham J, Leeming G, Ainsworth J. Computable Information Governance Contracts. Stud Health Technol Inform. 2017;235:476-480. PMID: 28423838.
Copy Download .nbib Format: NLM
Highly Charged Protein Ions: The Strongest Organic Acids to Date.

Angewandte Chemie (International ed. in English)

Zenaidee MA, Leeming MG, Zhang F, Funston TT, Donald WA.
PMID: 28471085
Angew Chem Int Ed Engl. 2017 Jul 10;56(29):8522-8526. doi: 10.1002/anie.201702781. Epub 2017 May 04.

The basicity of highly protonated cytochrome c (cyt c) and myoglobin (myo) ions were investigated using tandem mass spectrometry, ion-molecule reactions (IMRs), and theoretical calculations as a function of charge state. Surprisingly, highly charged protein ions (HCPI) can readily...

Cite
Zenaidee MA, Leeming MG, Zhang F, et al. Highly Charged Protein Ions: The Strongest Organic Acids to Date. Angew Chem Int Ed Engl. 2017;56(29):8522-8526doi: 10.1002/anie.201702781.
Zenaidee, M. A., Leeming, M. G., Zhang, F., Funston, T. T., & Donald, W. A. (2017). Highly Charged Protein Ions: The Strongest Organic Acids to Date. Angewandte Chemie (International ed. in English), 56(29), 8522-8526. https://doi.org/10.1002/anie.201702781
Zenaidee, Muhammad A, et al. "Highly Charged Protein Ions: The Strongest Organic Acids to Date." Angewandte Chemie (International ed. in English) vol. 56,29 (2017): 8522-8526. doi: https://doi.org/10.1002/anie.201702781
Zenaidee MA, Leeming MG, Zhang F, Funston TT, Donald WA. Highly Charged Protein Ions: The Strongest Organic Acids to Date. Angew Chem Int Ed Engl. 2017 Jul 10;56(29):8522-8526. doi: 10.1002/anie.201702781. Epub 2017 May 04. PMID: 28471085.
Copy Download .nbib Format: NLM
A vote for open refereeing.

Lancet (London, England)

Leeming RJ.
PMID: 10902663
Lancet. 2000 Jun 17;355(9221):2170. doi: 10.1016/S0140-6736(05)72803-8.

No abstract available.

Cite
Leeming RJ. A vote for open refereeing. Lancet. 2000;355(9221):2170doi: 10.1016/S0140-6736(05)72803-8.
Leeming, R. J. (2000). A vote for open refereeing. Lancet (London, England), 355(9221), 2170. https://doi.org/10.1016/S0140-6736(05)72803-8
Leeming, R J. "A vote for open refereeing." Lancet (London, England) vol. 355,9221 (2000): 2170. doi: https://doi.org/10.1016/S0140-6736(05)72803-8
Leeming RJ. A vote for open refereeing. Lancet. 2000 Jun 17;355(9221):2170. doi: 10.1016/S0140-6736(05)72803-8. PMID: 10902663.
Copy Download .nbib Format: NLM
Comparison of random amplified polymorphic DNA with restriction fragment length polymorphism as epidemiological typing methods for Mycobacterium tuberculosis.

Clinical molecular pathology

Linton CJ, Smart AD, Leeming JP, Jalal H, Telenti A, Bodmer T, Millar MR.
PMID: 16695993
Clin Mol Pathol. 1995 Jun;48(3):M133-5. doi: 10.1136/mp.48.3.m133.

Aim-To compare restriction fragment length polymorphism (RFLP) and random amplified polymorphic DNA (RAPD) methods for the epidemiological typing of Mycobacterium tuberculosis.Methods-Thirty one M tuberculosis cultures originating from patients in the Canton of Berne in Switzerland, which had previously been...

Cite
Linton CJ, Smart AD, Leeming JP, et al. Comparison of random amplified polymorphic DNA with restriction fragment length polymorphism as epidemiological typing methods for Mycobacterium tuberculosis. Clin Mol Pathol. 1995;48(3):M133-5doi: 10.1136/mp.48.3.m133.
Linton, C. J., Smart, A. D., Leeming, J. P., Jalal, H., Telenti, A., Bodmer, T., & Millar, M. R. (1995). Comparison of random amplified polymorphic DNA with restriction fragment length polymorphism as epidemiological typing methods for Mycobacterium tuberculosis. Clinical molecular pathology, 48(3), M133-5. https://doi.org/10.1136/mp.48.3.m133
Linton, C J, et al. "Comparison of random amplified polymorphic DNA with restriction fragment length polymorphism as epidemiological typing methods for Mycobacterium tuberculosis." Clinical molecular pathology vol. 48,3 (1995): M133-5. doi: https://doi.org/10.1136/mp.48.3.m133
Linton CJ, Smart AD, Leeming JP, Jalal H, Telenti A, Bodmer T, Millar MR. Comparison of random amplified polymorphic DNA with restriction fragment length polymorphism as epidemiological typing methods for Mycobacterium tuberculosis. Clin Mol Pathol. 1995 Jun;48(3):M133-5. doi: 10.1136/mp.48.3.m133. PMID: 16695993; PMCID: PMC407945.
Copy Download .nbib Format: NLM
Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid.

Clinical pharmacology : advances and applications

Gandy JJ, Meeding JP, Snyman JR, van Rensburg CE.
PMID: 22427734
Clin Pharmacol. 2012;4:7-11. doi: 10.2147/CPAA.S25784. Epub 2012 Feb 17.

BACKGROUND: The purpose of this research was to determine the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid (CHD-FA).METHODS: In this double-blind study, 30 male volunteers with predetermined atopy were randomly assigned to either Group A...

Cite
Gandy JJ, Meeding JP, Snyman JR, et al. Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. Clin Pharmacol. 2012;4:7-11doi: 10.2147/CPAA.S25784.
Gandy, J. J., Meeding, J. P., Snyman, J. R., & van Rensburg, C. E. (2012). Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. Clinical pharmacology : advances and applications, 47-11. https://doi.org/10.2147/CPAA.S25784
Gandy, Justin John, et al. "Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid." Clinical pharmacology : advances and applications vol. 4 (2012): 7-11. doi: https://doi.org/10.2147/CPAA.S25784
Gandy JJ, Meeding JP, Snyman JR, van Rensburg CE. Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. Clin Pharmacol. 2012;4:7-11. doi: 10.2147/CPAA.S25784. Epub 2012 Feb 17. PMID: 22427734; PMCID: PMC3304339.
Copy Download .nbib Format: NLM
Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis.

American journal of translational research

Vassiliadis E, Veidal SS, Kristiansen MN, Hansen C, Jorgensen M, Leeming DJ, Karsdal M.
PMID: 23724169
Am J Transl Res. 2013 May 24;5(4):465-9. Print 2013.

UNLABELLED: Having previously shown that levels of the citrullinated vimentin peptide VICM are raised in liver fibrosis in rats, we aimed to investigate whether inhibition of citrullination as measured by VICM levels could affect fibrogenesis.METHODS: Fibrogenesis was evaluated by...

Cite
Vassiliadis E, Veidal SS, Kristiansen MN, et al. Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis. Am J Transl Res. 2013;5(4):465-9
Vassiliadis, E., Veidal, S. S., Kristiansen, M. N., Hansen, C., Jorgensen, M., Leeming, D. J., & Karsdal, M. (2013). Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis. American journal of translational research, 5(4), 465-9.
Vassiliadis, Efstathios, et al. "Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis." American journal of translational research vol. 5,4 (2013): 465-9.
Vassiliadis E, Veidal SS, Kristiansen MN, Hansen C, Jorgensen M, Leeming DJ, Karsdal M. Peptidyl arginine deiminase inhibitor effect on hepatic fibrogenesis in a CCl4 pre-clinical model of liver fibrosis. Am J Transl Res. 2013 May 24;5(4):465-9. Print 2013. PMID: 23724169; PMCID: PMC3665919.
Copy Download .nbib Format: NLM
Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology.

American journal of translational research

Vassiliadis E, Oliveira CP, Alvares-da-Silva MR, Zhang C, Carrilho FJ, Stefano JT, Rabelo F, Pereira L, Kappel CR, Henriksen K, Veidal SS, Vainer B, Duffin KL, Christiansen C, Leeming DJ, Karsdal M.
PMID: 23145208
Am J Transl Res. 2012;4(4):403-14. Epub 2012 Oct 10.

AIM: To investigate whether increased levels of vimentin citrullinated peptides identified by MS in articular cartilage can be measured in pathologies other than rheumatoid arthritis and be utilised for diagnostic purposes.METHODS: A monoclonal antibody against the sequence RLRSSVPGV-citrulline (VICM)...

Cite
Vassiliadis E, Oliveira CP, Alvares-da-Silva MR, et al. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res. 2012;4(4):403-14
Vassiliadis, E., Oliveira, C. P., Alvares-da-Silva, M. R., Zhang, C., Carrilho, F. J., Stefano, J. T., Rabelo, F., Pereira, L., Kappel, C. R., Henriksen, K., Veidal, S. S., Vainer, B., Duffin, K. L., Christiansen, C., Leeming, D. J., & Karsdal, M. (2012). Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. American journal of translational research, 4(4), 403-14.
Vassiliadis, Efstathios, et al. "Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology." American journal of translational research vol. 4,4 (2012): 403-14.
Vassiliadis E, Oliveira CP, Alvares-da-Silva MR, Zhang C, Carrilho FJ, Stefano JT, Rabelo F, Pereira L, Kappel CR, Henriksen K, Veidal SS, Vainer B, Duffin KL, Christiansen C, Leeming DJ, Karsdal M. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res. 2012;4(4):403-14. Epub 2012 Oct 10. PMID: 23145208; PMCID: PMC3493028.
Copy Download .nbib Format: NLM
THE NATURAL DURATION OF CANCER.

British medical journal

Lazarus-Barlow WS, Leeming JH.
PMID: 20771693
Br Med J. 1924 Aug 16;2(3320):266-7. doi: 10.1136/bmj.2.3320.266.

No abstract available.

Cite
Lazarus-Barlow WS, Leeming JH. THE NATURAL DURATION OF CANCER. Br Med J. 1924;2(3320):266-7doi: 10.1136/bmj.2.3320.266.
Lazarus-Barlow, W. S., & Leeming, J. H. (1924). THE NATURAL DURATION OF CANCER. British medical journal, 2(3320), 266-7. https://doi.org/10.1136/bmj.2.3320.266
Lazarus-Barlow, W S, and Leeming, J H. "THE NATURAL DURATION OF CANCER." British medical journal vol. 2,3320 (1924): 266-7. doi: https://doi.org/10.1136/bmj.2.3320.266
Lazarus-Barlow WS, Leeming JH. THE NATURAL DURATION OF CANCER. Br Med J. 1924 Aug 16;2(3320):266-7. doi: 10.1136/bmj.2.3320.266. PMID: 20771693; PMCID: PMC2304825.
Copy Download .nbib Format: NLM
The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?.

Fibrogenesis & tissue repair

Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P.
PMID: 24678881
Fibrogenesis Tissue Repair. 2014 Mar 28;7(1):4. doi: 10.1186/1755-1536-7-4.

Interstitial fibrosis is the common endpoint of end-stage chronic kidney disease (CKD) leading to kidney failure. The clinical course of many renal diseases, and thereby of CKD, is highly variable. One of the major challenges in deciding which treatment...

Cite
Genovese F, Manresa AA, Leeming DJ, et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis Tissue Repair. 2014;7(1):4doi: 10.1186/1755-1536-7-4.
Genovese, F., Manresa, A. A., Leeming, D. J., Karsdal, M. A., & Boor, P. (2014). The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis & tissue repair, 7(1), 4. https://doi.org/10.1186/1755-1536-7-4
Genovese, Federica, et al. "The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?." Fibrogenesis & tissue repair vol. 7,1 (2014): 4. doi: https://doi.org/10.1186/1755-1536-7-4
Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?. Fibrogenesis Tissue Repair. 2014 Mar 28;7(1):4. doi: 10.1186/1755-1536-7-4. PMID: 24678881; PMCID: PMC3986639.
Copy Download .nbib Format: NLM
The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.

American journal of translational research

Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q, Suetta C, Henriksen K, Christiansen C, Karsdal MA, Leeming DJ.
PMID: 23634241
Am J Transl Res. 2013 Apr 19;5(3):303-15. Print 2013.

AIM: The present study describes the assessment of true formation of type III collagen in different pathologies using a neo-epitope specific competitive Enzyme-linked immunosorbent assay (ELISA) towards the N-terminal propeptide of type III collagen (PRO-C3).METHODS: The monoclonal antibody was...

Cite
Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5(3):303-15
Nielsen, M. J., Nedergaard, A. F., Sun, S., Veidal, S. S., Larsen, L., Zheng, Q., Suetta, C., Henriksen, K., Christiansen, C., Karsdal, M. A., & Leeming, D. J. (2013). The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. American journal of translational research, 5(3), 303-15.
Nielsen, Mette J, et al. "The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters." American journal of translational research vol. 5,3 (2013): 303-15.
Nielsen MJ, Nedergaard AF, Sun S, Veidal SS, Larsen L, Zheng Q, Suetta C, Henriksen K, Christiansen C, Karsdal MA, Leeming DJ. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013 Apr 19;5(3):303-15. Print 2013. PMID: 23634241; PMCID: PMC3633973.
Copy Download .nbib Format: NLM
Design and Development of a Novel Distance Learning Telementoring System Using Off-the-Shelf Materials and Software.

Surgical technology international

Rosser JC, Fleming JP, Legare TB, Choi KM, Nakagiri J, Griffith E.
PMID: 29301168
Surg Technol Int. 2017 Dec 22;31:41-49.

OBJECTIVE: To design and develop a distance learning (DL) system for the transference of laparoscopic surgery knowledge and skill constructed from off-the-shelf materials and commercially available software.INTRODUCTION: Minimally invasive surgery offers significant benefits over traditional surgical procedures, but adoption...

Cite
Rosser JC, Fleming JP, Legare TB, et al. Design and Development of a Novel Distance Learning Telementoring System Using Off-the-Shelf Materials and Software. Surg Technol Int. 2017;31:41-49
Rosser, J. C., Fleming, J. P., Legare, T. B., Choi, K. M., Nakagiri, J., & Griffith, E. (2017). Design and Development of a Novel Distance Learning Telementoring System Using Off-the-Shelf Materials and Software. Surgical technology international, 3141-49.
Rosser, James C, et al. "Design and Development of a Novel Distance Learning Telementoring System Using Off-the-Shelf Materials and Software." Surgical technology international vol. 31 (2017): 41-49.
Rosser JC, Fleming JP, Legare TB, Choi KM, Nakagiri J, Griffith E. Design and Development of a Novel Distance Learning Telementoring System Using Off-the-Shelf Materials and Software. Surg Technol Int. 2017 Dec 22;31:41-49. PMID: 29301168.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 148 entries